Why the study?
The mechanisms leading to fusion-independent ETS factor upregulation and prostate oncogenesis remain relatively unknown.
Does targeting ETV1 limit tumor growth in CIC and ERF-deficient prostate cancer?
Does targeting ETV1 limit tumor growth in CIC and ERF-deficient prostate cancer?
Concurrent loss of CIC and ERF drives prostate oncogenesis via fusion-independent ETV1 activation, which can be targeted to limit tumor growth.
CIC/ERF co-loss may drive prostate oncogenesis; hypothesis-generating for fusion-independent ETS mechanisms and needs clinical validation.
Human prostate cancer can result from chromosomal rearrangements that lead to aberrant ETS gene expression. The mechanisms that lead to fusion-independent ETS factor upregulation and prostate oncogenesis remain relatively unknown. Here, we show that two neighboring transcription factors, Capicua ( CIC ) and ETS2 repressor factor ( ERF ), which are co-deleted in human prostate tumors can drive prostate oncogenesis. Concurrent CIC and ERF loss commonly occur through focal genomic deletions at chromosome 19q13.2. Mechanistically, CIC and ERF co-bind the proximal regulatory element and mutually repress the ETS transcription factor, ETV1 . Targeting ETV1 in CIC and ERF -deficient prostate cancer limits tumor growth. Thus, we have uncovered a fusion-independent mode of ETS transcriptional activation defined by concurrent loss of CIC and ERF .
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: